TLSA vs. VYGR, NMRA, IMMP, ENGN, CADL, KOD, NGNE, RZLT, YMAB, and DMAC
Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Voyager Therapeutics (VYGR), Neumora Therapeutics (NMRA), Immutep (IMMP), enGene (ENGN), Candel Therapeutics (CADL), Kodiak Sciences (KOD), Neurogene (NGNE), Rezolute (RZLT), Y-mAbs Therapeutics (YMAB), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry.
Tiziana Life Sciences vs.
Voyager Therapeutics (NASDAQ:VYGR) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
48.0% of Voyager Therapeutics shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Voyager Therapeutics had 3 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 8 mentions for Voyager Therapeutics and 5 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.40 beat Voyager Therapeutics' score of 0.02 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.
Voyager Therapeutics currently has a consensus target price of $15.72, suggesting a potential upside of 272.42%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than Tiziana Life Sciences.
Voyager Therapeutics received 299 more outperform votes than Tiziana Life Sciences when rated by MarketBeat users. Likewise, 67.75% of users gave Voyager Therapeutics an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote.
Voyager Therapeutics has higher revenue and earnings than Tiziana Life Sciences.
Voyager Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
Voyager Therapeutics has a net margin of 15.80% compared to Tiziana Life Sciences' net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Tiziana Life Sciences' return on equity.
Summary
Voyager Therapeutics beats Tiziana Life Sciences on 14 of the 16 factors compared between the two stocks.
Get Tiziana Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tiziana Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:TLSA) was last updated on 2/22/2025 by MarketBeat.com Staff
